脓毒症生物标志物：综述。
Sepsis biomarkers: a review.
机构信息
Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, route de Lennik 808, 1070 Brussels, Belgium.
出版信息
Crit Care. 2010;14(1):R15. doi: 10.1186/cc8872. Epub 2010 Feb 9.
Abstract
INTRODUCTION
Biomarkers can be useful for identifying or ruling out sepsis, identifying patients who may benefit from specific therapies or assessing the response to therapy.
METHODS
We used an electronic search of the PubMed database using the key words "sepsis" and "biomarker" to identify clinical and experimental studies which evaluated a biomarker in sepsis.
RESULTS
The search retrieved 3370 references covering 178 different biomarkers.
CONCLUSIONS
Many biomarkers have been evaluated for use in sepsis. Most of the biomarkers had been tested clinically, primarily as prognostic markers in sepsis; relatively few have been used for diagnosis. None has sufficient specificity or sensitivity to be routinely employed in clinical practice. PCT and CRP have been most widely used, but even these have limited ability to distinguish sepsis from other inflammatory conditions or to predict outcome.
摘要
简介
生物标志物可用于识别或排除败血症，确定可能受益于特定治疗的患者，或评估治疗反应。
方法
我们使用 PubMed 数据库的电子搜索，使用关键词“败血症”和“生物标志物”来识别评估败血症中生物标志物的临床和实验研究。
结果
搜索共检索到 3370 篇参考文献，涵盖了 178 种不同的生物标志物。
结论
已经评估了许多生物标志物在败血症中的应用。大多数生物标志物已经在临床上进行了测试，主要作为败血症的预后标志物；用于诊断的相对较少。没有一种标志物具有足够的特异性或灵敏度，可以在临床实践中常规使用。降钙素原和 C 反应蛋白应用最广泛，但即使是这些标志物，也很难区分败血症与其他炎症性疾病，或预测结局。
相似文献
1
Sepsis biomarkers: a review.脓毒症生物标志物：综述。
Crit Care. 2010;14(1):R15. doi: 10.1186/cc8872. Epub 2010 Feb 9.
2
The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills?降钙素原作为脓毒症管理中生物标志物的功效：屠龙之举还是徒劳无功？
Surg Infect (Larchmt). 2013 Dec;14(6):489-511. doi: 10.1089/sur.2012.028. Epub 2013 Nov 25.
3
Early increases in serum FGF21 levels predict mortality of septic patients.早期血清 FGF21 水平升高可预测脓毒症患者的死亡率。
Cytokine. 2018 Nov;111:428-433. doi: 10.1016/j.cyto.2018.05.020. Epub 2018 Jun 1.
4
Real-world use of procalcitonin and other biomarkers among sepsis hospitalizations in the United States: A retrospective, observational study.美国脓毒症住院患者中降钙素原和其他生物标志物的实际应用：一项回顾性观察研究。
PLoS One. 2018 Oct 17;13(10):e0205924. doi: 10.1371/journal.pone.0205924. eCollection 2018.
5
Comparison between white blood cell count, procalcitonin and C reactive protein as diagnostic and prognostic biomarkers of infection or sepsis in patients presenting to emergency department.急诊科就诊患者中白细胞计数、降钙素原和C反应蛋白作为感染或脓毒症诊断及预后生物标志物的比较
Clin Chem Lab Med. 2014 Oct;52(10):1465-72. doi: 10.1515/cclm-2014-0210.
6
The Use of Biomarkers in Sepsis: A Systematic Review.生物标志物在脓毒症中的应用：一项系统综述。
Curr Pharm Biotechnol. 2017;18(6):499-507. doi: 10.2174/1389201018666170601080111.
7
Biomarkers of sepsis: time for a reappraisal.脓毒症的生物标志物：重新评估的时候到了。
Crit Care. 2020 Jun 5;24(1):287. doi: 10.1186/s13054-020-02993-5.
8
Interleukin-10 and interleukin-1 receptor antagonist distinguish between patients with sepsis and the systemic inflammatory response syndrome (SIRS).白细胞介素-10 和白细胞介素-1 受体拮抗剂可区分脓毒症和全身炎症反应综合征 (SIRS) 患者。
Cytokine. 2019 Aug;120:227-233. doi: 10.1016/j.cyto.2019.05.015. Epub 2019 May 21.
9
Lipidomic profile and candidate biomarkers in septic patients.脓毒症患者的脂质组学特征和候选生物标志物。
Lipids Health Dis. 2020 Apr 13;19(1):68. doi: 10.1186/s12944-020-01246-2.
10
Measuring both procalcitonin and C-reactive protein for a diagnosis of sepsis in critically ill patients.检测降钙素原和C反应蛋白以诊断重症患者的脓毒症。
J Int Med Res. 2014 Aug;42(4):1050-9. doi: 10.1177/0300060514528483. Epub 2014 May 14.
引用本文的文献
1
Sepsis detection in hematologic and solid tumor malignancies using quantitative inflammatory biomarker differences in a prospective single center study.在一项前瞻性单中心研究中，利用定量炎症生物标志物差异检测血液系统和实体瘤恶性肿瘤中的脓毒症。
Sci Rep. 2025 Aug 28;15(1):31701. doi: 10.1038/s41598-025-15784-1.
2
Co-Evaluation of Lactate, Base Excess, and Albumin as Predictors of Mortality in Sepsis by Excluding the Factors That Affect Their Levels: An Observational Study.通过排除影响乳酸、碱剩余和白蛋白水平的因素对脓毒症死亡率预测指标进行联合评估：一项观察性研究
Biomedicines. 2025 Aug 8;13(8):1932. doi: 10.3390/biomedicines13081932.
3
Lower Initial Insulin-like Growth Factor-Binding Protein-3 Concentrations May Reflect Immune Suppression and Predict Increased Risk of Sepsis-Related Mortality.较低的初始胰岛素样生长因子结合蛋白-3浓度可能反映免疫抑制，并预示脓毒症相关死亡率增加的风险。
Int J Mol Sci. 2025 Jul 8;26(14):6549. doi: 10.3390/ijms26146549.
4
Biomarkers to guide sepsis management.用于指导脓毒症管理的生物标志物。
Ann Intensive Care. 2025 Jul 21;15(1):103. doi: 10.1186/s13613-025-01524-1.
5
Association of heparin-binding protein with risk of in-hospital heart failure in patients with acute coronary syndrome.肝素结合蛋白与急性冠状动脉综合征患者院内发生心力衰竭风险的关联
Am J Transl Res. 2025 Jun 15;17(6):4237-4246. doi: 10.62347/LQLD9274. eCollection 2025.
6
Point of care sepsis diagnosis: Exploring microfluidic techniques for sample preparation, biomarker isolation, and detection.床旁脓毒症诊断：探索用于样品制备、生物标志物分离和检测的微流控技术。
Biomicrofluidics. 2025 Jul 1;19(4):041502. doi: 10.1063/5.0248096. eCollection 2025 Jul.
7
L-shape association between serum chloride and 365-day mortality in critically ill patients with sepsis based on the MIMIC-IV database.基于MIMIC-IV数据库的脓毒症重症患者血清氯与365天死亡率的L型关联
Sci Rep. 2025 Jul 1;15(1):20391. doi: 10.1038/s41598-025-08630-x.
8
A Knowledge-Enhanced Platform (MetaSepsisKnowHub) for Retrieval Augmented Generation-Based Sepsis Heterogeneity and Personalized Management: Development Study.用于基于检索增强生成的脓毒症异质性和个性化管理的知识增强平台（MetaSepsisKnowHub）：开发研究
J Med Internet Res. 2025 Jun 6;27:e67201. doi: 10.2196/67201.
9
Intensive care infection score: ICIS discriminates between infected and uninfected critically ill patients in routine intensive care unit practice.重症监护感染评分：在常规重症监护病房实践中，重症监护感染评分（ICIS）可区分感染和未感染的重症患者。
Intensive Care Med Exp. 2025 Jun 5;13(1):58. doi: 10.1186/s40635-025-00767-3.
10
Battle of the Biomarkers of Systemic Inflammation.全身炎症生物标志物之战
Biology (Basel). 2025 Apr 18;14(4):438. doi: 10.3390/biology14040438.
本文引用的文献
1
Biomarkers of sepsis.脓毒症的生物标志物
Crit Care Med. 2009 Jul;37(7):2290-8. doi: 10.1097/CCM.0b013e3181a02afc.
2
Serial cytokine levels in patients with severe sepsis.严重脓毒症患者的细胞因子水平的动态变化。
Inflamm Res. 2009 Jul;58(7):385-93. doi: 10.1007/s00011-009-0003-0. Epub 2009 Mar 5.
3
Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS.开发一种使用液相色谱-串联质谱法灵敏且定量测定人血清中铁调素的方法。
J Pharmacol Toxicol Methods. 2009 May-Jun;59(3):171-80. doi: 10.1016/j.vascn.2009.02.004. Epub 2009 Feb 28.
4
Efficacy of procalcitonin in the early diagnosis of bacterial infections in a critical care unit.降钙素原在重症监护病房细菌感染早期诊断中的效能
Shock. 2009 Jun;31(6):586-91. doi: 10.1097/SHK.0b013e31819716fa.
5
Implementation of the Surviving Sepsis Campaign guidelines for severe sepsis and septic shock: we could go faster.《拯救脓毒症运动严重脓毒症和脓毒性休克指南》的实施：我们可以更快推进。
J Crit Care. 2008 Dec;23(4):455-60. doi: 10.1016/j.jcrc.2007.08.003. Epub 2007 Dec 11.
6
A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis.一项前瞻性、多中心研究，旨在推导一个生物标志物组合，以评估急诊科疑似脓毒症患者发生器官功能障碍、休克和死亡的风险。
Crit Care Med. 2009 Jan;37(1):96-104. doi: 10.1097/CCM.0b013e318192fd9d.
7
Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care.降钙素原指导下的抗生素使用与初级保健中急性呼吸道感染的标准治疗方法对比
Arch Intern Med. 2008 Oct 13;168(18):2000-7; discussion 2007-8. doi: 10.1001/archinte.168.18.2000.
8
Utility of interleukin-12 and interleukin-10 in comparison with other cytokines and acute-phase reactants in the diagnosis of neonatal sepsis.与其他细胞因子和急性期反应物相比，白细胞介素-12和白细胞介素-10在新生儿败血症诊断中的效用。
Am J Perinatol. 2008 Nov;25(10):629-36. doi: 10.1055/s-0028-1090585. Epub 2008 Oct 10.
9
B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients.B型利钠肽作为重症监护患者脓毒症诱发心肌抑制的标志物。
Crit Care Med. 2008 Nov;36(11):3030-7. doi: 10.1097/CCM.0b013e31818b9153.
10
Serum levels of osteopontin are increased in SIRS and sepsis.全身炎症反应综合征（SIRS）和脓毒症患者血清骨桥蛋白水平升高。
Intensive Care Med. 2008 Dec;34(12):2176-84. doi: 10.1007/s00134-008-1268-4. Epub 2008 Sep 20.
Zotero 插件